Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

Menée aux Etats-Unis, cette étude analyse la survenue d'événements indésirables de nature immmunitaire chez des patients atteints d'un cancer traité par anti-PD-1

Résumé en anglais

Immune checkpoint inhibitors (ICIs) that target the programmed death 1 receptor (anti–programmed cell death 1 [PD-1] therapy) have ushered in a new era of cancer therapy. However, their application has been curtailed by serious immune-related adverse events (irAEs), such as colitis, pneumonitis, and myocarditis, that remain largely unpredictable. Although the use of tumor mutational burden (TMB) as a biomarker for expected therapy response has been advocated,1 a similar parameter for irAEs is lacking. In an attempt to fill this clinically relevant knowledge gap, we investigated the association between irAEs reported during anti–PD-1 therapy and TMB by comparing large-scale surveillance data of irAEs with the median TMB across multiple cancer types.